$CLNN
Clene Inc. Stock $clnn

$clnn Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-Q Financial Statement

#000143774923023409 Filed on August 14, 2023

Income Statement

Concept	2023 Q3	2023 Q2
Revenue	$108.0K	$269.0K
YoY Change	-37.93%	668.57%
Cost Of Revenue	$12.00K	$66.00K
YoY Change	-36.84%
Gross Profit	$96.00K	$203.0K
YoY Change	-38.06%	480.0%
Gross Profit Margin	88.89%	75.46%
Selling, General & Admin	$3.600M	$3.857M
YoY Change	3.15%	-12.28%
% of Gross Profit	3750.0%	1900.0%
Research & Development	$5.972M	$6.615M
YoY Change	-6.73%	-27.83%
% of Gross Profit	6220.83%	3258.62%
Depreciation & Amortization	$439.0K	$442.0K
YoY Change	88.41%	54.01%
% of Gross Profit	457.29%	217.73%
Operating Expenses	$5.972M	$6.615M
YoY Change	-40.15%	-51.47%
Operating Profit	-$9.542M	-$10.34M
YoY Change	-2.68%	-23.97%
Interest Expense	$1.188M	$1.104M
YoY Change	-148.53%	47.0%
% of Operating Profit
Other Income/Expense, Net	$7.124M	-$14.81M
YoY Change	-708.37%	-263.41%
Pretax Income	-$2.418M	-$25.14M
YoY Change	-77.97%	454.54%
Income Tax	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$2.418M	-$25.14M
YoY Change	-77.97%	454.54%
Net Earnings / Revenue	-2238.89%	-9346.84%
Basic Earnings Per Share	-$0.02	-$0.29
Diluted Earnings Per Share	-$0.02	-$0.29
COMMON SHARES
Basic Shares Outstanding	128.4M	78.39M
Diluted Shares Outstanding

Balance Sheet

Concept	2023 Q3	2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$42.11M	$49.24M
YoY Change	159.41%	87.34%
Cash & Equivalents	$42.11M	$49.24M
Short-Term Investments	$0.00	$0.00
Other Short-Term Assets	$1.029M	$883.0K
YoY Change	-70.52%	-71.0%
Inventory	$104.0K	$52.00K
Prepaid Expenses
Receivables	$64.00K	$161.0K
Other Receivables	$1.090M	$858.0K
Total Short-Term Assets	$46.45M	$53.37M
YoY Change	116.17%	68.97%
LONG-TERM ASSETS
Property, Plant & Equipment	$13.93M	$14.42M
YoY Change	42.83%	78.22%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$60.00K	$58.00K
YoY Change	3.45%	0.0%
Total Long-Term Assets	$13.99M	$14.47M
YoY Change	-3.66%	11.73%
TOTAL ASSETS
Total Short-Term Assets	$46.45M	$53.37M
Total Long-Term Assets	$13.99M	$14.47M
Total Assets	$60.43M	$67.85M
YoY Change	67.85%	52.32%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.889M	$846.0K
YoY Change	-45.31%	-81.31%
Accrued Expenses	$3.194M	$4.298M
YoY Change	49.53%	67.5%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$9.630M	$62.00K
YoY Change	9827.84%	-49.59%
Total Short-Term Liabilities	$15.27M	$5.735M
YoY Change	148.1%	-25.08%
LONG-TERM LIABILITIES
Long-Term Debt	$16.65M	$25.84M
YoY Change	-18.91%	27.19%
Other Long-Term Liabilities	$7.110M	$14.74M
YoY Change	-61.85%	-13.99%
Total Long-Term Liabilities	$23.76M	$40.58M
YoY Change	-39.34%	8.35%
TOTAL LIABILITIES
Total Short-Term Liabilities	$15.27M	$5.735M
Total Long-Term Liabilities	$23.76M	$40.58M
Total Liabilities	$39.03M	$46.31M
YoY Change	-13.89%	2.68%
SHAREHOLDERS EQUITY
Retained Earnings	-$232.6M	-$230.1M
YoY Change	21.02%	26.99%
Common Stock	$13.00K	$13.00K
YoY Change	116.67%	116.67%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$21.41M	$21.53M
YoY Change
Total Liabilities & Shareholders Equity	$60.43M	$67.85M
YoY Change	67.85%	52.32%

Cashflow Statement

Concept	2023 Q3	2023 Q2
OPERATING ACTIVITIES
Net Income	-$2.418M	-$25.14M
YoY Change	-77.97%	454.54%
Depreciation, Depletion And Amortization	$439.0K	$442.0K
YoY Change	88.41%	54.01%
Cash From Operating Activities	-$6.760M	-$7.021M
YoY Change	-20.29%	-27.84%
INVESTING ACTIVITIES
Capital Expenditures	$50.00K	-$39.00K
YoY Change	-103.02%	-95.61%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00
YoY Change	-100.0%	-100.0%
Cash From Investing Activities	-$50.00K	$39.00K
YoY Change	-100.59%	-98.94%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-240.0K	37.83M
YoY Change	-360.87%	6803.28%
NET CHANGE
Cash From Operating Activities	-6.760M	-7.021M
Cash From Investing Activities	-50.00K	39.00K
Cash From Financing Activities	-240.0K	37.83M
Net Change In Cash	-7.050M	30.85M
YoY Change	-32145.45%	-659.14%
FREE CASH FLOW
Cash From Operating Activities	-$6.760M	-$7.021M
Capital Expenditures	$50.00K	-$39.00K
Free Cash Flow	-$6.810M	-$6.982M
YoY Change	-0.25%	-21.04%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	128401112
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	128401112
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	74759591
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	74759591
CY2022Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	74759591
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	74759591
CY2023Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-06-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	01-39834
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	85-2828339
	dei	Entity Address Address Line1 EntityAddressAddressLine1	6550 South Millrock Drive, Suite G50
	dei	Entity Address City Or Town EntityAddressCityOrTown	Salt Lake City
	dei	Entity Address State Or Province EntityAddressStateOrProvince	UT
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	84121
	dei	City Area Code CityAreaCode	801
	dei	Local Phone Number LocalPhoneNumber	676 9695
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	128404735
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	49243000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18332000	usd
CY2023Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	0	usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	4983000	usd
CY2023Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	161000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	189000	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	52000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	43000	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3915000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5648000	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	53371000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	29195000	usd
CY2023Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	58000	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	58000	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4383000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4602000	usd
CY2023Q2	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	10033000	usd
CY2022Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	10638000	usd
CY2023Q2	us-gaap	Assets Assets	67845000	usd
CY2022Q4	us-gaap	Assets Assets	44493000	usd
CY2023Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	846000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3014000	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4298000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3863000	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	529000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	488000	usd
CY2023Q2	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	62000	usd
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	74000	usd
CY2023Q2	us-gaap	Notes Payable Current NotesPayableCurrent	0	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	6418000	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	5735000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	13857000	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5235000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5557000	usd
CY2023Q2	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	0	usd
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	34000	usd
CY2023Q2	us-gaap	Long Term Notes Payable LongTermNotesPayable	16017000	usd
CY2022Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	9483000	usd
CY2023Q2	clnn	Convertible Note Payable Noncurrent ConvertibleNotePayableNoncurrent	9822000	usd
CY2022Q4	clnn	Convertible Note Payable Noncurrent ConvertibleNotePayableNoncurrent	9770000	usd
CY2023Q2	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	8201000	usd
CY2022Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	0	usd
CY2023Q2	clnn	Clene Nanomedicine Contingent Earnout CleneNanomedicineContingentEarnout	1154000	usd
CY2022Q4	clnn	Clene Nanomedicine Contingent Earnout CleneNanomedicineContingentEarnout	2264000	usd
CY2023Q2	clnn	Initial Shareholders Contingent Earnout InitialShareholdersContingentEarnout	148000	usd
CY2022Q4	clnn	Initial Shareholders Contingent Earnout InitialShareholdersContingentEarnout	291000	usd
CY2023Q2	us-gaap	Liabilities Liabilities	46312000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	41256000	usd
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	13000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	7000	usd
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	251478000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	196246000	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-230132000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-193219000	usd
CY2023Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	174000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	203000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	21533000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	3237000	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	67845000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	44493000	usd
CY2023Q2	us-gaap	Revenues Revenues	269000	usd
CY2022Q2	us-gaap	Revenues Revenues	35000	usd
	us-gaap	Revenues Revenues	376000	usd
	us-gaap	Revenues Revenues	65000	usd
CY2023Q2	us-gaap	Cost Of Revenue CostOfRevenue	66000	usd
CY2022Q2	us-gaap	Cost Of Revenue CostOfRevenue	0	usd
	us-gaap	Cost Of Revenue CostOfRevenue	71000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	0	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6615000	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9166000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	14010000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17746000	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3924000	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4464000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7363000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9250000	usd
CY2023Q2	us-gaap	Costs And Expenses CostsAndExpenses	10605000	usd
CY2022Q2	us-gaap	Costs And Expenses CostsAndExpenses	13630000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	21444000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	26996000	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-10336000	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-13595000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-21068000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-26931000	usd
CY2023Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	213000	usd
CY2022Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	61000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	385000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	85000	usd
CY2023Q2	us-gaap	Interest Expense InterestExpense	1104000	usd
CY2022Q2	us-gaap	Interest Expense InterestExpense	751000	usd
	us-gaap	Interest Expense InterestExpense	2170000	usd
	us-gaap	Interest Expense InterestExpense	1533000	usd
CY2023Q2	us-gaap	Gain Loss On Contract Termination GainLossOnContractTermination	0	usd
CY2022Q2	us-gaap	Gain Loss On Contract Termination GainLossOnContractTermination	0	usd
	us-gaap	Gain Loss On Contract Termination GainLossOnContractTermination	0	usd
	us-gaap	Gain Loss On Contract Termination GainLossOnContractTermination	420000	usd
CY2023Q2	clnn	Purchase Agreement Commitment Share Expense PurchaseAgreementCommitmentShareExpense	3000	usd
CY2022Q2	clnn	Purchase Agreement Commitment Share Expense PurchaseAgreementCommitmentShareExpense	-0	usd
	clnn	Purchase Agreement Commitment Share Expense PurchaseAgreementCommitmentShareExpense	402000	usd
	clnn	Purchase Agreement Commitment Share Expense PurchaseAgreementCommitmentShareExpense	-0	usd
CY2023Q2	clnn	Issuance Costs For Common Stock Warrant Liability IssuanceCostsForCommonStockWarrantLiability	333000	usd
CY2022Q2	clnn	Issuance Costs For Common Stock Warrant Liability IssuanceCostsForCommonStockWarrantLiability	-0	usd
	clnn	Issuance Costs For Common Stock Warrant Liability IssuanceCostsForCommonStockWarrantLiability	333000	usd
	clnn	Issuance Costs For Common Stock Warrant Liability IssuanceCostsForCommonStockWarrantLiability	-0	usd
CY2023Q2	clnn	Gain Loss On Issuance Of Equity GainLossOnIssuanceOfEquity	-14840000	usd
CY2022Q2	clnn	Gain Loss On Issuance Of Equity GainLossOnIssuanceOfEquity	0	usd
	clnn	Gain Loss On Issuance Of Equity GainLossOnIssuanceOfEquity	-14840000	usd
	clnn	Gain Loss On Issuance Of Equity GainLossOnIssuanceOfEquity	0	usd
CY2023Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	383000	usd
CY2022Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-20000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	383000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-2000	usd
CY2023Q2	clnn	Change In Fair Value Of Contingent Earnout ChangeInFairValueOfContingentEarnout	1165000	usd
CY2022Q2	clnn	Change In Fair Value Of Contingent Earnout ChangeInFairValueOfContingentEarnout	8310000	usd
	clnn	Change In Fair Value Of Contingent Earnout ChangeInFairValueOfContingentEarnout	1110000	usd
	clnn	Change In Fair Value Of Contingent Earnout ChangeInFairValueOfContingentEarnout	8253000	usd
CY2023Q2	clnn	Change In Fair Value Of Initial Shareholders Contingent Earnout ChangeInFairValueOfInitialShareholdersContingentEarnout	150000	usd
CY2022Q2	clnn	Change In Fair Value Of Initial Shareholders Contingent Earnout ChangeInFairValueOfInitialShareholdersContingentEarnout	1066000	usd
	clnn	Change In Fair Value Of Initial Shareholders Contingent Earnout ChangeInFairValueOfInitialShareholdersContingentEarnout	143000	usd
	clnn	Change In Fair Value Of Initial Shareholders Contingent Earnout ChangeInFairValueOfInitialShareholdersContingentEarnout	1054000	usd
CY2023Q2	us-gaap	Government Assistance Amount GovernmentAssistanceAmount	341000	usd
CY2022Q2	us-gaap	Government Assistance Amount GovernmentAssistanceAmount	356000	usd
	us-gaap	Government Assistance Amount GovernmentAssistanceAmount	655000	usd
	us-gaap	Government Assistance Amount GovernmentAssistanceAmount	655000	usd
CY2023Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-13000	usd
CY2022Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-10000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	107000	usd
CY2023Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-14807000	usd
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	9061000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-15845000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	9043000	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-25143000	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4534000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-36913000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-17888000	usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-25143000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-4534000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-36913000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-17888000	usd
CY2023Q2	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	6000	usd
CY2022Q2	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	-37000	usd
	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	20000	usd
	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	-87000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-53000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-110000	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-49000	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-60000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-47000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-147000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-29000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-147000	usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-25190000	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4681000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-36942000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-18035000	usd
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.29
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.46
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.28
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	86050405
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	63335271
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	81077661
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	63095400
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	3237000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	4665000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2223000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	14000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	4000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-11770000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-1627000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	40929000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	4970000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2451000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	usd
CY2023Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	6000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-53000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-25143000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	21533000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	12597000	usd
CY2022Q1	clnn	Reclassification Of Common Stock Warrant Liability To Permanent Equity ReclassificationOfCommonStockWarrantLiabilityToPermanentEquity	305000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	267000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2202000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-50000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	50000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-13354000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	2017000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	17000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2184000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	usd
CY2022Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-37000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	100000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-110000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-4534000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-563000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-36913000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-17888000	usd
	us-gaap	Depreciation Depreciation	844000	usd
	us-gaap	Depreciation Depreciation	482000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	219000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	183000	usd
	clnn	Purchase Agreement Commitment Share Expense PurchaseAgreementCommitmentShareExpense	402000	usd
	clnn	Purchase Agreement Commitment Share Expense PurchaseAgreementCommitmentShareExpense	0	usd
	clnn	Issuance Costs For Common Stock Warrant Liability IssuanceCostsForCommonStockWarrantLiability	333000	usd
	clnn	Issuance Costs For Common Stock Warrant Liability IssuanceCostsForCommonStockWarrantLiability	0	usd
	clnn	Gain Loss On Issuance Of Equity GainLossOnIssuanceOfEquity	-14840000	usd
	clnn	Gain Loss On Issuance Of Equity GainLossOnIssuanceOfEquity	-0	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	383000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-2000	usd
	clnn	Change In Fair Value Of Contingent Earnout ChangeInFairValueOfContingentEarnout	1110000	usd
	clnn	Change In Fair Value Of Contingent Earnout ChangeInFairValueOfContingentEarnout	8253000	usd
	clnn	Change In Fair Value Of Initial Shareholders Contingent Earnout ChangeInFairValueOfInitialShareholdersContingentEarnout	143000	usd
	clnn	Change In Fair Value Of Initial Shareholders Contingent Earnout ChangeInFairValueOfInitialShareholdersContingentEarnout	1054000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	4674000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	4386000	usd
	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease	-0	usd
	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease	420000	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	508000	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	442000	usd
	clnn	Non Cash Interest Income Expense NonCashInterestIncomeExpense	-186000	usd
	clnn	Non Cash Interest Income Expense NonCashInterestIncomeExpense	-72000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-28000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-49000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	9000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	66000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1733000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	989000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2168000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1528000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	235000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1044000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-281000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-240000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16239000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-22814000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	-0	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	24549000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	5000000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	2500000	usd
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	0	usd
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	3016000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	239000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1824000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	4761000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-20857000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	284000	usd
	clnn	Proceeds From Issuance Of Common Stock And Warrants Net Of Offering Costs ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfOfferingCosts	42114000	usd
	clnn	Proceeds From Issuance Of Common Stock And Warrants Net Of Offering Costs ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfOfferingCosts	0	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	46000	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	65000	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	350000	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	694000	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	-0	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	30000	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	-0	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	100000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	42418000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	783000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-29000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-147000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	30911000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-43035000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	18390000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	50346000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	49301000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	7311000	usd
CY2023Q2	us-gaap	Cash Cash	49243000	usd
CY2022Q2	us-gaap	Cash Cash	7253000	usd
CY2023Q2	us-gaap	Restricted Cash RestrictedCash	58000	usd
CY2022Q2	us-gaap	Restricted Cash RestrictedCash	58000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	49301000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7311000	usd
	clnn	Accrued Liability For Debt Modification Fees AccruedLiabilityForDebtModificationFees	200000	usd
	clnn	Accrued Liability For Debt Modification Fees AccruedLiabilityForDebtModificationFees	0	usd
	clnn	Common Stock Warrant Liability Recorded Upon Debt Modification CommonStockWarrantLiabilityRecordedUponDebtModification	692000	usd
	clnn	Common Stock Warrant Liability Recorded Upon Debt Modification CommonStockWarrantLiabilityRecordedUponDebtModification	0	usd
	clnn	Common Stock Warrant Liability Recorded Upon Public Stock Offering CommonStockWarrantLiabilityRecordedUponPublicStockOffering	7126000	usd
	clnn	Common Stock Warrant Liability Recorded Upon Public Stock Offering CommonStockWarrantLiabilityRecordedUponPublicStockOffering	0	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2343000	usd
	clnn	Lease Incentive Realized LeaseIncentiveRealized	0	usd
	clnn	Lease Incentive Realized LeaseIncentiveRealized	500000	usd
	clnn	Lease Liability Settled Through Termination Of Lease LeaseLiabilitySettledThroughTerminationOfLease	0	usd
	clnn	Lease Liability Settled Through Termination Of Lease LeaseLiabilitySettledThroughTerminationOfLease	602000	usd
	clnn	Reclassification Of Common Stock Warrant Liability To Permanent Equity ReclassificationOfCommonStockWarrantLiabilityToPermanentEquity	0	usd
	clnn	Reclassification Of Common Stock Warrant Liability To Permanent Equity ReclassificationOfCommonStockWarrantLiabilityToPermanentEquity	305000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1075000	usd
	us-gaap	Interest Paid Net InterestPaidNet	1985000	usd
	us-gaap	Interest Paid Net InterestPaidNet	1013000	usd
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-10300000	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-13600000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-21100000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-26900000	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-230100000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-193200000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	49200000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	23300000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16200000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-22800000	usd
	clnn	Minimum Cash Balance For Loan Covenant MinimumCashBalanceForLoanCovenant	5000000.0	usd
CY2023Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	37400000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Use of Estimates</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 25pt;">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and disclosure of contingent assets and liabilities, and the reported amounts of expenses. We base our estimates on historical experience and various other assumptions that we believe to be reasonable. Actual results <em style="font: inherit;"> may </em>differ from those estimates or assumptions. Estimates are periodically reviewed in light of changes in circumstances, facts, and experience, and any changes in estimates will be recorded in future periods as they develop.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2023Q2	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	0	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1231000	usd
CY2023Q2	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	0	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1129000	usd
CY2023Q2	us-gaap	Finance Lease Liability Payments Due Year Five FinanceLeaseLiabilityPaymentsDueYearFive	0	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	1092000	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Concentrations of Credit Risk</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 25pt;">Financial instruments which potentially subject us to significant concentrations of credit risk consist primarily of cash. Our cash is held in financial institutions and amounts on deposit <em style="font: inherit;"> may </em>at times exceed federally insured limits. We have <em style="font: inherit;">not</em> experienced any losses on our deposits of cash and do <em style="font: inherit;">not</em> believe that we are subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2023Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	38000	usd
CY2023Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	14000	usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	29000	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	14000	usd
CY2023Q2	us-gaap	Finance Lease Liability Payments Due After Year Five FinanceLeaseLiabilityPaymentsDueAfterYearFive	0	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	1694000	usd
CY2023Q2	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	64000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	8001000	usd
CY2023Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	0	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	4997000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	14000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	4983000	usd
CY2023Q2	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	5000000	usd
CY2022Q2	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	2500000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	5000000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	2500000	usd
CY2023Q2	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	0	usd
CY2022Q2	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	3016000	usd
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	0	usd
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	3016000	usd
CY2023Q2	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	5000000	usd
CY2022Q2	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	5516000	usd
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	5000000	usd
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	5516000	usd
CY2023Q2	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	2000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	2237000	usd
CY2023Q2	us-gaap	Finance Lease Liability FinanceLeaseLiability	62000	usd
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	5764000	usd
CY2023Q2	us-gaap	Government Assistance Amount Cumulative GovernmentAssistanceAmountCumulative	858000	usd
CY2022Q4	us-gaap	Government Assistance Amount Cumulative GovernmentAssistanceAmountCumulative	2777000	usd
CY2023Q2	us-gaap	Supplies Supplies	2174000	usd
CY2022Q4	us-gaap	Supplies Supplies	2290000	usd
CY2023Q2	us-gaap	Other Assets Current OtherAssetsCurrent	883000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	581000	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3915000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5648000	usd
CY2023Q2	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	16135000	usd
CY2022Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	15911000	usd
CY2023Q2	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	6102000	usd
CY2022Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	5273000	usd
CY2023Q2	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	10033000	usd
CY2022Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	10638000	usd
CY2023Q2	us-gaap	Depreciation Depreciation	442000	usd
CY2022Q2	us-gaap	Depreciation Depreciation	287000	usd
	us-gaap	Depreciation Depreciation	844000	usd
	us-gaap	Depreciation Depreciation	482000	usd
CY2023Q2	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	62000	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	529000	usd
CY2023Q2	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	0	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5235000	usd
CY2023Q2	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	1039000	usd
CY2022Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	2007000	usd
CY2023Q2	clnn	Accrued Cro And Clinical Fees AccruedCroAndClinicalFees	2716000	usd
CY2022Q4	clnn	Accrued Cro And Clinical Fees AccruedCroAndClinicalFees	1297000	usd
CY2023Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	543000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	559000	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4298000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3863000	usd
CY2023Q2	clnn	Number Of Real Estate Leases NumberOfRealEstateLeases	3	pure
CY2023Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.096	pure
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.096	pure
CY2023Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y9M18D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y3M18D
CY2023Q2	us-gaap	Finance Lease Right Of Use Asset Before Accumulated Amortization FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization	636000	usd
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset Before Accumulated Amortization FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization	636000	usd
CY2023Q2	us-gaap	Finance Lease Right Of Use Asset Accumulated Amortization FinanceLeaseRightOfUseAssetAccumulatedAmortization	367000	usd
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset Accumulated Amortization FinanceLeaseRightOfUseAssetAccumulatedAmortization	326000	usd
CY2023Q2	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	269000	usd
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	310000	usd
CY2023Q2	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.109	pure
CY2022Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.102	pure
CY2023Q2	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P0Y10M24D
CY2022Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P1Y2M12D
CY2023Q2	us-gaap	Finance Lease Liability Payments Remainder Of Fiscal Year FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear	37000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	481000	usd
CY2023Q2	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	27000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1172000	usd
CY2023Q2	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	0	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1202000	usd
CY2023Q2	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	21000	usd
CY2022Q2	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	21000	usd
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	41000	usd
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	41000	usd
CY2023Q2	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	3000	usd
CY2022Q2	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	1000	usd
	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	9000	usd
	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	6000	usd
CY2023Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	251000	usd
CY2022Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	209000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	504000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	439000	usd
CY2023Q2	us-gaap	Short Term Lease Cost ShortTermLeaseCost	2000	usd
CY2022Q2	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0	usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	2000	usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0	usd
CY2023Q2	us-gaap	Variable Lease Cost VariableLeaseCost	72000	usd
CY2022Q2	us-gaap	Variable Lease Cost VariableLeaseCost	108000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	122000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	173000	usd
CY2023Q2	us-gaap	Lease Cost LeaseCost	349000	usd
CY2022Q2	us-gaap	Lease Cost LeaseCost	339000	usd
	us-gaap	Lease Cost LeaseCost	678000	usd
	us-gaap	Lease Cost LeaseCost	659000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	628000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	612000	usd
	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	9000	usd
	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	6000	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	46000	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	65000	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-24856000	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-3398000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-36402000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-16355000	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-287000	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-1136000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-511000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-1533000	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-25143000	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4534000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-36913000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-17888000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000	pure
	us-gaap	Net Income Loss NetIncomeLoss	-36913000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-17888000	usd
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	86050405
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	63335271
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	81077661
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2451000	usd
CY2022Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2184000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4674000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4386000	usd
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2451000	usd
CY2022Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2184000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4674000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4386000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	15260297
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.98
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y3M10D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	2348000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	6361362
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.97
	clnn	Sharebased Compensation Arrangement By Sharebased Payment Award Options Grants In Period Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm	P9Y11M4D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	394609
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	5.43
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	21227050
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.33
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y8M15D
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1879000	usd
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	8546494
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.79
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y2M23D
CY2023Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	1879000	usd
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	21227050
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	2.33
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P7Y8M15D
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	1879000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.77
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.24
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-4534000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	43479
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.15
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	10870
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	1.15
CY2023Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	37000	usd
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P0Y8M23D
CY2022Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	0	usd
CY2023Q2	clnn	Clene Nanomedicine Contingent Earnout Fair Value Disclosure CleneNanomedicineContingentEarnoutFairValueDisclosure	1154000	usd
CY2023Q2	clnn	Initial Shareholders Contingent Earnout Fair Value Disclosure InitialShareholdersContingentEarnoutFairValueDisclosure	148000	usd
CY2022Q4	clnn	Clene Nanomedicine Contingent Earnout Fair Value Disclosure CleneNanomedicineContingentEarnoutFairValueDisclosure	2264000	usd
CY2022Q4	clnn	Initial Shareholders Contingent Earnout Fair Value Disclosure InitialShareholdersContingentEarnoutFairValueDisclosure	291000	usd
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	128401112
CY2023Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2023Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	105432083
CY2022Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	4477045
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-25143000	usd
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	63095400
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.29
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.46
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.28
CY2023Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	135785172
CY2022Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	24472573
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	135785172
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	24472573
CY2023Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	269000	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	35000	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	376000	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	65000	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-10336000	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-13595000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-21068000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-26931000	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-10336000	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-13595000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-21068000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-26931000	usd
CY2023Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-14807000	usd
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	9061000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-15845000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	9043000	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-25143000	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4534000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-36913000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-17888000	usd
CY2023Q2	us-gaap	Assets Assets	67845000	usd
CY2022Q4	us-gaap	Assets Assets	44493000	usd

Files In Submission

Name	View Source	Status
clnn-20230630_lab.xml	Edgar Link	unprocessable
clnn-20230630_def.xml	Edgar Link	unprocessable
0001437749-23-023409-index-headers.html	Edgar Link	pending
0001437749-23-023409-index.html	Edgar Link	pending
0001437749-23-023409.txt	Edgar Link	pending
0001437749-23-023409-xbrl.zip	Edgar Link	pending
clnn-20230630.xsd	Edgar Link	pending
clnn20230630_10q.htm	Edgar Link	pending
ex_528470.htm	Edgar Link	pending
ex_528471.htm	Edgar Link	pending
ex_528472.htm	Edgar Link	pending
ex_528473.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
img.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
clnn-20230630_cal.xml	Edgar Link	unprocessable
clnn-20230630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
clnn20230630_10q_htm.xml	Edgar Link	completed
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CLNN
Clene Inc. Stock $clnn

2023 Q3 Form 10-Q Financial Statement

#000143774923023409 Filed on August 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CLNN Clene Inc. Stock $clnn

2023 Q3 Form 10-Q Financial Statement

#000143774923023409 Filed on August 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CLNN
Clene Inc. Stock $clnn